SGX Stocks and Warrants

Keppel Land: Chinese home sales still healthy

kimeng
Publish date: Wed, 16 Apr 2014, 09:41 AM
kimeng
0 5,634
Keeping track of stocks and warrants news
  • 1Q14 results in line
  • Highline condo launch ahead
  • Chinese home sales still firm

1Q14 numbers hit by absence of taxwrite

Keppel Land (KPLD) reported 1Q14 PATMI of S$87.7m, decreasing 9.2% YoY mostly due to the absence of a tax write-back recognized in the same period last year. Contributions from the property development segment decreased 37.4% YoY to S$35.6m as The Botanica Ph.6 and Marina Bay Suites achieved TOP over the year; this dip was partially offset by an 8.9% increase in property investment income to S$29.3m from Keppel REIT and MBFC T3. We judge this set of results to be mostly in line with expectations and YTD PATMI now constitutes 19.7% of our full year forecast. 1Q14 topline came in at S$284.9m, up 37.6% as revenues from Chinese development projects increased.

Highline Residences to launch in 2Q14

The group sold 54 homes in Singapore over 1Q14, mostly from The Glades which is now 23% sold (~170 out of 726 units). The run rate over 1Q14 so far represents 14.5% of the 370 total units sold in FY13, in line with expectations for a fairly muted FY14 in terms of SG home sales given the weak outlook. In 2Q14, we expect KPLD to launch its condominium project in Tiong Bahru, Highline Residences; pricing will likely be a key driver for launch performance here, in our view. In China, 570 home units were sold over the quarter, down 33% YoY versus the 850 units sold in 1Q13, though management highlights that the achieved sales value was actually 5.9% higher due to a change in mix to higher-end projects. KPLD also reports that sales had slowed over Jan-Feb due to the winter weather and Lunar New Year holidays, but it has since seen sales pick up in Mar-14.

Maintain BUY with unchanged S$4.09 FV

We continue to like KPLD for its compelling valuation and its strong balance sheet with S$1.0b in cash and 40% net gearing. Maintain BUY with an unchanged fair value estimate of S$4.09 (30% discount to RNAV).

Source: OCBC Research - 16 Apr 2014

Related Stocks
Market Buzz
Discussions
Be the first to like this. Showing 0 of 0 comments

Post a Comment